These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 33988072)
1. Low LIM-domain only 2 (LMO2) expression in aggressive B cell lymphoma correlates with Chapman J; Verdun RE; Lossos IS Leuk Lymphoma; 2021 Oct; 62(10):2547-2550. PubMed ID: 33988072 [No Abstract] [Full Text] [Related]
2. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. Tibiletti MG; Martin V; Bernasconi B; Del Curto B; Pecciarini L; Uccella S; Pruneri G; Ponzoni M; Mazzucchelli L; Martinelli G; Ferreri AJ; Pinotti G; Assanelli A; Scandurra M; Doglioni C; Zucca E; Capella C; Bertoni F Hum Pathol; 2009 May; 40(5):645-52. PubMed ID: 19144384 [TBL] [Abstract][Full Text] [Related]
3. Clinical Significance of Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907 [No Abstract] [Full Text] [Related]
4. High expression of LMO2 in Hodgkin, Burkitt and germinal center diffuse large B cell lymphomas. Shams TM J Egypt Natl Canc Inst; 2011 Dec; 23(4):147-53. PubMed ID: 22776842 [TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234 [TBL] [Abstract][Full Text] [Related]
6. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis. Li S; Desai P; Lin P; Yin CC; Tang G; Wang XJ; Konoplev SN; Khoury JD; Bueso-Ramos CE; Medeiros LJ Histopathology; 2016 Jun; 68(7):1090-8. PubMed ID: 26426741 [TBL] [Abstract][Full Text] [Related]
8. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis. Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193 [TBL] [Abstract][Full Text] [Related]
9. Genomic profile of TdT Hamdan H; Luu L; Opsahl M; Weinberg O; Fuda F; Koduru P; Wilson K; Gagan J; Ramakrishnan Geethakumari P; Collins R; Chen W Cytometry B Clin Cytom; 2022 Nov; 102(6):448-450. PubMed ID: 36102633 [No Abstract] [Full Text] [Related]
10. Cutaneous involvement of high-grade B-cell lymphoma with MYC and BCL6 rearrangements: A case report. Maejima E; Oishi N; Ogawa Y; Okamoto T; Mitsui H; Shimada S; Kawamura T J Dermatol; 2023 Aug; 50(8):e243-e244. PubMed ID: 36890662 [No Abstract] [Full Text] [Related]
11. Diagnostic value of STMN1, LMO2, HGAL, AID expression and 1p36 chromosomal abnormalities in primary cutaneous B cell lymphomas. Verdanet E; Dereure O; René C; Tempier A; Benammar-Hafidi A; Gallo M; Frouin E; Durand L; Gazagne I; Costes-Martineau V; Cacheux V; Szablewski V Histopathology; 2017 Oct; 71(4):648-660. PubMed ID: 28594133 [TBL] [Abstract][Full Text] [Related]
12. Round-robin testing for LMO2 and MYC as immunohistochemical markers to screen MYC rearrangements in aggressive large B-cell lymphoma. Papaleo N; Climent F; Tapia G; Luizaga L; Azcarate J; Bosch-Schips J; Muñoz-Marmol AM; Salido M; Lome-Maldonado C; Vazquez I; Colomo L Virchows Arch; 2024 Aug; 485(2):307-314. PubMed ID: 37368083 [TBL] [Abstract][Full Text] [Related]
13. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. Ennishi D; Jiang A; Boyle M; Collinge B; Grande BM; Ben-Neriah S; Rushton C; Tang J; Thomas N; Slack GW; Farinha P; Takata K; Miyata-Takata T; Craig J; Mottok A; Meissner B; Saberi S; Bashashati A; Villa D; Savage KJ; Sehn LH; Kridel R; Mungall AJ; Marra MA; Shah SP; Steidl C; Connors JM; Gascoyne RD; Morin RD; Scott DW J Clin Oncol; 2019 Jan; 37(3):190-201. PubMed ID: 30523716 [TBL] [Abstract][Full Text] [Related]
15. Lack of expression of LMO2 clone SP51 identifies MYC rearrangements in aggressive large B-cell lymphomas. Vazquez I; Papaleo N; Lop J; Puiggros A; Sanchez-Gonzalez B; Diez-Feijoo R; Gimeno E; Andrade-Campos M; Salar A; Espinet B; Salido M; Tapia G; Carreras J; Ferrer A; Arenillas L; Calvo X; Colomo L Virchows Arch; 2021 Dec; 479(6):1073-1078. PubMed ID: 33811533 [TBL] [Abstract][Full Text] [Related]
16. High-grade B-cell lymphoma with MYC and BCL2 rearrangements presenting as a cervical mass. Lin C; Kuma L; Shen L Pathology; 2024 Jun; 56(4):588-590. PubMed ID: 37940480 [No Abstract] [Full Text] [Related]
17. BCL6--regulated by AhR/ARNT and wild-type MEF2B--drives expression of germinal center markers MYBL1 and LMO2. Ding J; Dirks WG; Ehrentraut S; Geffers R; MacLeod RA; Nagel S; Pommerenke C; Romani J; Scherr M; Vaas LA; Zaborski M; Drexler HG; Quentmeier H Haematologica; 2015 Jun; 100(6):801-9. PubMed ID: 25769544 [TBL] [Abstract][Full Text] [Related]
18. Lymphomas with pseudo-double-hit BCL6-MYC translocations due to t(3;8)(q27;q24) are associated with a germinal center immunophenotype, extranodal involvement, and frequent BCL2 translocations. Johnson SM; Umakanthan JM; Yuan J; Fedoriw Y; Bociek RG; Kaiser-Rogers K; Sanmann JN; Montgomery ND Hum Pathol; 2018 Oct; 80():192-200. PubMed ID: 29902576 [TBL] [Abstract][Full Text] [Related]
19. EBV Liu H; Xu-Monette ZY; Tang G; Wang W; Kim Y; Yuan J; Li Y; Chen W; Li Y; Fedoriw GY; Zhu F; Fang X; Luedke C; Medeiros LJ; Young KH; Hu S Histopathology; 2022 Feb; 80(3):575-588. PubMed ID: 34637146 [TBL] [Abstract][Full Text] [Related]
20. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Visco C; Tzankov A; Xu-Monette ZY; Miranda RN; Tai YC; Li Y; Liu WM; d'Amore ES; Li Y; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Wang HY; Dunphy CH; His ED; Zhao XF; Choi WW; Zhao X; van Krieken JH; Huang Q; Ai W; O'Neill S; Ponzoni M; Ferreri AJ; Kahl BS; Winter JN; Go RS; Dirnhofer S; Piris MA; Møller MB; Wu L; Medeiros LJ; Young KH Haematologica; 2013 Feb; 98(2):255-63. PubMed ID: 22929980 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]